Influencing factors and prognostic value of ESR, hs-CRP, IL-6 and D-D in patients with tuberculous polyserous effusion

doi:10.11958/20221856

Abstract

Abstract:

Objective To explore the influencing factors of prognostic value of erythrocyte sedimentation rate (ESR), interleukin (IL) -6, hypersensitive C-reactive protein (hs-CRP) and D-dimer (D-D) in patients with tuberculous polyserous effusion. Methods A total of 228 hospitalized patients with tuberculous polyserous effusion were collected and divided into the poor prognosis group (89 cases) and the good prognosis group (139 cases) according to the outcome. Baseline characteristics, tuberculosis disease related data and leukocyte (WBC), neutrophil ratio (neutrophil %), ESR, PLT, procalcitonin (PCT), hs-CRP, IL-6, serum albumin (ALB) and D-D were collected within 24 h after admission. Multivariate Logistic regression was used to analyze the influencing factors of poor prognosis in inpatients with tuberculous polyserous effusion. Receiver operating characteristic curve (ROC) was used to analyze the diagnostic value of each indicator for poor prognosis. Results Levels of NEUT%, ESR, hs-CRP, IL-6 and D-D were significantly higher in the poor prognosis group than those in the good prognosis group (P<0.05). Increased levels of ESR, hs-CRP, IL-6 and D-D were risk factors for poor prognosis in inpatients with tuberculous polyserous effusion (P<0.05). The joint prediction model was established as logit (P) =-6.650+0.050×(ESR)+0.008×(hs-CRP)+0.024×(IL-6)+0.251×(D-D). ROC curve analysis showed that the largest area under the curve (AUC) was ESR, which was 0.819 (95%CI: 0.766-0.873). The AUC of ESR+IL-6+hs-CRP+D-D combined detection was 0.905 (95%CI: 0.865-0.945). Conclusion The combined detection of ESR, hs-CRP, IL-6 and D-D has a certain predictive value for the prognosis of tuberculous polyserous effusion.

Key words: tuberculosis, pleural effusion, blood sedimentation, C-reactive protein, interleukin-6, fibrin fibrinogen degradation products, prognosis, polyserositis

CLC Number:

Figures/Tables 8

Tab.1 Comparison of general data between the good prognosis group and the poor prognosis group

组别	n		年龄（岁）	性别（男/女）		民族（汉族/其他）	发病时间（<2周/2周~ 1个月/>1个月）					结核治疗史（初治/复治）			合并其他部位结核感染（是/否）			糖尿病病史（有/无）
预后良好组	139		53（28，67）	85/54		123/16	44/60/35					134/5			124/15			11/128
预后不良组	89		53（31，68）	50/39		82/7	20/36/33					83/6			81/8			5/84
Z、χ²或P			0.319	0.555		0.795	4.301					0.347^▲			0.194			0.438
组别		PPD试验（阴性/弱阳性/阳性/强阳性）			痰结核杆菌抗酸染色涂片（阴性/阳性）			发病部位
组别		PPD试验（阴性/弱阳性/阳性/强阳性）			痰结核杆菌抗酸染色涂片（阴性/阳性）			①	②	③	④		⑤	⑥		⑦	⑧	⑨	⑩
预后良好组		85/6/34/14			120/19			12	3	3	9		12	1		43	25	29	2
预后不良组		65/5/11/8			75/14			7	2	0	7		1	3		38	11	20	0
χ²或P		0.130^▲			0.186			0.102^▲

Tab.2 Comparison of laboratory indexes between the poor prognosis group and the good prognosis group

组别		n	WBC（×10⁹/L）		NEUT%		PLT（×10⁹/L）
预后良好组		139	6.13（4.79，8.04）		73.40（67.80，81.20）		287（210，396）
预后不良组		89	6.82（4.94，8.91）		76.70（70.90，82.97）		302（204，411）
Z			1.349		2.059^＊		0.534
组别	ESR（mm/1 h）			PCT（μg/L）		hs-CRP（mg/L）
预后良好组	32（15，47）			0.159（0.056，0.308）		44.45（17.15，109.85）
预后不良组	62（40，88）			0.168（0.063，0.245）		159.92（55.86，282.77）
Z	8.134^＊＊			1.187		7.301^＊＊
组别			IL-6（ng/L）			ALB（g/L）	D-D（mg/L）
预后良好组			27.17（12.99，63.35）			31.71 $±$ 5.75	2.46（1.38，3.24）
预后不良组			77.27（39.71，115.85）			31.83 $±$ 6.52	2.83（1.59，3.60）
t或Z			7.064^＊＊			0.514	1.983^＊

Tab.2 Comparison of laboratory indexes between the poor prognosis group and the good prognosis group

组别		n	WBC（×10⁹/L）		NEUT%		PLT（×10⁹/L）
预后良好组		139	6.13（4.79，8.04）		73.40（67.80，81.20）		287（210，396）
预后不良组		89	6.82（4.94，8.91）		76.70（70.90，82.97）		302（204，411）
Z			1.349		2.059^＊		0.534
组别	ESR（mm/1 h）			PCT（μg/L）		hs-CRP（mg/L）
预后良好组	32（15，47）			0.159（0.056，0.308）		44.45（17.15，109.85）
预后不良组	62（40，88）			0.168（0.063，0.245）		159.92（55.86，282.77）
Z	8.134^＊＊			1.187		7.301^＊＊
组别			IL-6（ng/L）			ALB（g/L）	D-D（mg/L）
预后良好组			27.17（12.99，63.35）			31.71 $±$ 5.75	2.46（1.38，3.24）
预后不良组			77.27（39.71，115.85）			31.83 $±$ 6.52	2.83（1.59，3.60）
t或Z			7.064^＊＊			0.514	1.983^＊

Tab.3 Logistic regression analysis of factors affecting poor prognosis of hospitalized patients with tuberculous polyserous effusion

变量	B	SE	Wald χ²	P	OR	OR 95%CI
NEUT%	0.014	0.018	0.652	0.419	1.014	0.980~1.050
ESR	0.050	0.010	27.820	<0.001	1.051	1.032~1.071
hs-CRP	0.008	0.002	9.736	0.002	1.008	1.003~1.012
IL-6	0.024	0.006	14.560	<0.001	1.024	1.012~1.037
D-D	0.251	0.114	4.830	0.028	1.285	1.027~1.607
常数项	-6.650	1.528	18.940	<0.001	0.001

Tab.4 Analysis of the diagnostic value of single index for poor prognosis

指标	AUC（95%CI）	P	临界值	敏感度（%）	特异度（%）	约登指数
ESR	0.819（0.766~0.873）	<0.001	48.50 mm/1 h	67.4	77.0	0.444
hs-CRP	0.787（0.728~0.846）	<0.001	212.09 mg/L	44.9	98.6	0.435
IL-6	0.777（0.717~0.838）	<0.001	76.06 ng/L	51.7	92.1	0.438
D-D	0.578（0.500~0.656）	0.048	2.65 mg/L	59.6	69.8	0.293

Fig.1 Analysis of the diagnostic value of single index in poor prognosis of tuberculous pleural effusion

Fig.2 Analysis of the diagnostic value of the combination of the two indexes for the poor prognosis of tuberculous pleural effusion

Fig.3 Analysis of the diagnostic value of three and four indexes combined in poor prognosis of tuberculous pleural effusion

Tab.5 Analysis of the diagnostic value of multiple indexes combined with indexes for poor prognosis

指标	AUC（95%CI）	P	敏感度（%）	特异度（%）	约登指数
ESR+IL-6	0.881（0.835~0.927）	<0.001	77.5	87.1	0.646
ESR+hs-CRP	0.875（0.829~0.920）	<0.001	67.4	92.8	0.602
ESR+D-D	0.823（0.770~0.876）	<0.001	56.2	90.6	0.468
IL-6+hs-CRP	0.826（0.772~0.881）	<0.001	65.2	89.2	0.544
IL-6+D-D	0.784（0.724~0.844）	<0.001	57.3	85.6	0.429
hs-CRP+D-D	0.804（0.747~0.861）	<0.001	82.0	64.0	0.461
ESR+IL-6+hs-CRP	0.896（0.854~0.938）	<0.001	83.1	83.5	0.666
ESR+IL-6+D-D	0.889（0.845~0.932）	<0.001	75.3	89.9	0.599
ESR+hs-CRP+D-D	0.878（0.832~0.923）	<0.001	76.4	83.5	0.652
IL-6+hs-CRP+D-D	0.846（0.795~0.897）	<0.001	64.0	90.6	0.547
ESR+IL-6+hs-CRP+D-D	0.905（0.865~0.945）	<0.001	85.4	80.6	0.660

References 23

[1]	World Health Organization. Global tuberculosis report 2022[EB/OL]. (2022-10-27)[2022-11-01]. https://www.who.int/publications/i/item/9789240061729.
[2]	周建, 陈慧娟, 洪峰, 等. 2013-2018年贵州省肺结核发病人群特征分析[J]. 现代预防医学, 2020, 47(9):1541-1546.
	ZHOU J, CHEN H J, HONG F, et al. Characteristics of tuberculosis patients in Guizhou,2013-2018[J]. Modern Preventive Medicine, 2020, 47(9):1541-1546.
[3]	马晓雪, 周建, 田娟, 等. 2015-2020年贵州省肺结核时空分布特征分析[J]. 现代预防医学, 2021, 48(18):3415-3420.
	MA X X, ZHOU J, TIAN J, et al. Spatial and temporal distribution characteristics of pulmonary tuberculo-sis in Guizhou Province from 2015 to 2020[J]. Modern Preventive Medicine, 2021, 48(18):3415-3420.
[4]	黄忠峰. 70例结核性多浆膜腔积液的临床分析[J]. 中国实用医药, 2008, 3(27):114-115.
	HUANG Z F. Clinical analysis of 70 cases of tuberculous polyserous effusion[J]. China Prac Med, 2008, 3(27):114-115. doi:10.3969/j.issn.1673-7555.2008.27.079.
[5]	任运华. 50例结核性多浆膜腔积液分析[J]. 吉林医学, 2012, 33(1):175.
	REN Y H. Analysis of tuberculous polyserous effusion in 50 cases[J]. Jilin Medical Journal, 2012, 33(1):175. doi:10.3969/j.issn.1004-0412.2012.01.115.
[6]	刘洪兰. 影响结核性多浆膜腔积液疗效的因素[J]. 临床肺科杂志, 2014, 19(12):2300-2302.
	LIU H L. Factors influencing the curative effect of tuberculous polyserous effusion[J]. Journal of Clinical Pulmonary Medicine, 2014, 19(12):2300-2302. doi:10.3969/j.issn.1009-6663.2014.012.057.
[7]	王黎霞, 成诗明, 周林, 等. 肺结核诊断WS288—2017[J]. 中国感染控制杂志, 2018, 17(7):642-652.
	WANG L X, CHENG S M, ZHOU L, et al. Diagnosis of tuberculosis[J]. Chin J Infect Control, 2018, 17(7):642-652. doi:10.3969/j.issn.1671-9638.2018.07.019.
[8]	中华医学会结核病学分会. 肺结核诊断和治疗指南[J]. 中国实用乡村医生杂志, 2013, 20(2):7-11.
	Tuberculosis Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of tuberculosis[J]. Chinese Practical Journal of Rural Doctor, 2013, 20(2):7-11. doi:10.3969/j.issn.1672-7185.2013.02.005.
[19]	PANG Y, AN J, SHU W, et al. Epidemiology of extrapulmonary tuberculosis among inpatients,China,2008-2017[J]. Emerg Infect Dis, 2019, 25(3):457-464. doi:10.3201/eid2503.180572.
[10]	GAO L, LI X, LIU J, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China:follow-up results of a population-based,multicentre,prospective cohort study[J]. Lancet Infect Dis, 2017, 17(10):1053-1061. doi:10.1016/S1473-3099(17)30402-4.
[11]	CAO G, RAO J, CAI Y, et al. Analysis of treatment and prognosis of 863 patients with spinal tuberculosis in Guizhou Province[J]. Biomed Res Int, 2018, 2018:3265735. doi:10.1155/2018/3265735.
[12]	冯雄, 郑友彬. 活动性肺结核患者血清超敏C反应蛋白血沉水平变化与预后关系分析[J]. 河北医学, 2020, 26(8):1260-1264.
	FENG X, ZHENG Y B. Analysis on the relationship between the changes of serum hs-CRP,ESR and prognosis in patients with active tuberculosis[J]. Hebei Medicine, 2020, 26(8):1260-1264. doi:10.3969/j.issn.1006-6233.2020.08.007.
[13]	张国. 肺结核患者血清GM-CSF、hs-CRP水平与患者病情进展及预后评估的相关性研究[J]. 检验医学与临床, 2017, 14(2):263-264.
	ZHANG G. Correlation of serum GM-CSF and hs-CRP levels with disease progression and prognosis in patients with pulmonary tuberculosis[J]. Lab Med Clin, 2017, 14(2):263-264. doi:10.3969/j.issn.1672-9455.2017.02.042.
[14]	郭新美, 吴海良, 王庆, 等. 非耐药结核性渗出性胸膜炎规律治疗下胸水难吸收的原因探讨[J]. 中国现代医学杂志, 2010, 20(4):571-574.
	GUO X M, WU H L, WANG Q, et al. Causes of difficult absorption of pleural effusion in drug-sensitive tuberculous exudative pleurisy under regular treatment[J]. China Journal of Modern Medicine, 2010, 20(4):571-574.
[15]	SCHULMAN H, NIWARD K, ABATE E, et al. Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis[J]. Int J Tuberc Lung Dis, 2019, 23(11):1155-1161. doi:10.5588/ijtld.18.0634.
[16]	GUPTE A N, KUMAR P, ARAÚJO-PEREIRA M, et al. Baseline IL-6 is a biomarker for unfavourable tuberculosis treatment outcomes:a multisite discovery and validation study[J]. Eur Respir J, 2022, 59(4):2100905. doi:10.1183/13993003.00905-2021.
[17]	JOSHI L, PONNANA M, SIVANGALA R, et al. Evaluation of TNF-α,IL-10 and IL-6 cytokine production and their correlation with genotype variants amongst tuberculosis patients and their household contacts[J]. PLoS One, 2015, 10(9):e137727. doi:10.1371/journal.pone.0137727.
[18]	BONI F G, HAMDI I, KOUNDI L M, et al. Cytokine storm in tuberculosis and IL-6 involvement[J]. Infect Genet Evol, 2022, 97:105166. doi:10.1016/j.meegid.2021.105166.
[19]	NAN G Y, FEI H, ZHEN W, et al. Risk factors associated with venous thromboembolism in tuberculosis:A case control study[J]. Clin Respir J, 2022, 16(12):835-841. doi:10.1111/crj.13555.
[20]	KUTIYAL A S, GUPTA N, GARG S, et al. A study of haematological and haemostasis parameters and hypercoagulable state in tuberculosis patients in Northern India and the outcome with anti-tubercular therapy[J]. J Clin Diagn Res, 2017, 11(2):OC09-OC13. doi:10.7860/JCDR/2017/24022.9249.
[21]	武舒佳, 张瑶, 武军驻, 等. 中性粒细胞在结核病发展和转归过程中的变化及应用[J]. 中华传染病杂志, 2021, 39(8):515-518.
	WU S J, ZHANG Y, WU J Z, et al. Changes and application of neutrophils in the development and outcome of tuberculosis[J]. Chinese Journal of Infectious Diseases, 2021, 39(8):515-518. doi:10.3760/cma.j.cn311365-20200513-00592.
[22]	MUEFONG C N, SUTHERLAND J S. Neutrophils in tuberculosis-associated inflammation and lung pathology[J]. Front Immunol, 2020, 11:962. doi:10.3389/fimmu.2020.00962.
[23]	BORKUTE R R, WOELKE S, PEI G, et al. Neutrophils in tuberculosis:cell biology,cellular networking and multitasking in host defense[J]. Int J Mol Sci, 2021, 22(9):4801. doi:10.3390/ijms22094801.

[1]	YANG Min, PAN Yansha, ZHANG Changling, CHEN Hongying, GUO Qulian, LIU Wenjun. Correlation analysis of baseline data, early treatment response and prognosis in children with acute lymphoblastic leukemia [J]. Tianjin Medical Journal, 2024, 52(9): 954-958.
[2]	JIAO Aiju, REN Baolong, ZHANG Chunhua, LI Wenrui, ZHAO Weijing. The predictive value of NIHSS score combined with serum BDNF and IL-6 for post-stroke depression [J]. Tianjin Medical Journal, 2024, 52(9): 963-966.
[3]	WANG Xinbo, LUO Bingqing, SHI Yubao, ZHANG Ye, XI Jiangwei. Expression of LncRNA LINC00342 and miR-203a-3p in colorectal cancer tissue and their relationship with prognosis [J]. Tianjin Medical Journal, 2024, 52(9): 971-976.
[4]	DAI Yao, FANG Xiang, HUANG Kang, FENG Jie, LIU Min, WU Songbai. Clinical curative effect of HAT therapy on septic shock [J]. Tianjin Medical Journal, 2024, 52(8): 825-829.
[5]	ZHANG Xiyou, GUO Yidan, ZHANG Chunxia, ZHOU Xiaoling, JIA Meng, SHI Zhihua, LUO Yang. Clinical research of the correlation between hyperkalemia and adverse outcome events in elderly patients with maintenance hemodialysis [J]. Tianjin Medical Journal, 2024, 52(8): 840-844.
[6]	MAN Yi, XU Ya, HE Xiancheng, SONG Shaofeng, LIU Aiguo. Relationship between expression levels of EGFR, Ki-67, P53 and CTC and the prognosis of triple negative breast cancer [J]. Tianjin Medical Journal, 2024, 52(8): 862-867.
[7]	LI Li, CAO Shuming, YANG Zhongping, HU Ruomei. Effects of fish collagen oligopeptide on operative prognosis of patients with emergency complex hand trauma [J]. Tianjin Medical Journal, 2024, 52(8): 868-871.
[8]	LUO Yanran, SHI Xiaofei, HAN Lei, ZHANG Bei, WEN Luyao. Research progress of dermatomyositis-related autoantibodies in interstitial lung disease [J]. Tianjin Medical Journal, 2024, 52(7): 704-708.
[9]	LI Yong, SU Yakun, ZHANG Hongbo, LI Yuan, LI Zhanhu, YAN Xiaoju. Clinical significance of serum asprosin level in patients with early renal damage of essential hypertension [J]. Tianjin Medical Journal, 2024, 52(6): 609-613.
[10]	XUE Jing, YUAN Xiaodong, XING Aijun, WANG Lianhui, MA Qian, FU Yongshan, ZHANG Pingshu. Relationship between sleep-wake biorhythm and prognosis in patients with acute ischemic stroke [J]. Tianjin Medical Journal, 2024, 52(6): 614-619.
[11]	YE Zhaoyang, MA Jianzhong, LI Houjun, WEI Kunpeng. Relationship between peripheral blood TLR4, IL-1β and NLR and the progression and prognosis of acute pancreatitis [J]. Tianjin Medical Journal, 2024, 52(6): 648-652.
[12]	SHAO Hongxia, WU Juanjuan, YU Hongzhi, WU Qi, WU Junping. Clinical features of hematogenous disseminated pulmonary tuberculosis complicated with intracranial tuberculosis [J]. Tianjin Medical Journal, 2024, 52(5): 495-498.
[13]	LYU Mengna, LI Jianbin, WU Rui. Early predictors of the severity of COVID-19 in patients with autoinflammatory diseases [J]. Tianjin Medical Journal, 2024, 52(5): 528-531.
[14]	WU Jikun, XU Rongdi, XU Jinghan, WANG Le, CONG Hongliang. Validation and comparison of 6 common model scores in predicting long-term prognosis in patients with NSTEMI [J]. Tianjin Medical Journal, 2024, 52(5): 541-547.
[15]	ZHU Yongyi, WEN Bolun, WU Qinglin, LIANG Shaoling, ZONG Yindong. Effect of dexmedetomidine on shivering and hemodynamics during spinal anesthesia in pregnant and postpartum women [J]. Tianjin Medical Journal, 2024, 52(4): 387-390.